Meeting News

Meeting News

On location

Researchers Validate Burkitt Lymphoma Prognostic Index

Researchers have created a prognostic index specific to Burkitt lymphoma (BL) that will allow for simplified stratification and comparison of risk distribution in geographically...
On location

Thiotepa-Containing Conditioning Regimens Improve Survival Outcomes in Patients With PCNSL

Thiotepa-containing conditioning regimens, including thiotepa/busulfan/cyclophosphamide (TBC) and thiotepa/carmustine (TT-BCNU), were associated with favorable survival outcomes in patients with primary diffuse large B-cell lymphoma of...
On location

Durable Efficacy With LOXO-305 in Heavily Pretreated CLL/SLL

LOXO-305, a highly selective noncovalent Bruton tyrosine kinase (BTK) inhibitor, was associated with promising response and efficacy rates in patients with heavily pretreated and...
On location

MLL Associated With Worse Post-Transplant Outcomes Than Other Cytogenetic Factors

In an analysis comparing the effects of MLL translocations with other cytogenetic characteristics on post-transplant outcomes in acute myeloid leukemia (AML), investigators found that...
On location

Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL/SLL

The availability of B-cell receptor inhibitors (BCRis) and other novel agents for the treatment of chronic lymphocytic leukemia (CLL) has reshaped the treatment paradigm...
On location

Early-Phase Study Shows Promising Response Rates With Venetoclax Plus Navitoclax in ALL

Nearly half of patients with relapsed/refractory acute lymphocytic leukemia (ALL) had a complete response (CR) after treatment with a combination of venetoclax and navitoclax,...
On location

Daratumumab-Based Induction and Response-Adapted Consolidation Induces MRD Negativity in Patients With Newly Diagnosed Myeloma

Induction therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) followed by autologous transplant and Dara-KRd consolidation guided by measurable residual disease (MRD) leads to...

Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma

Adding the antibiotic clarithromycin to lenalidomide plus dexamethasone improved the response rate in patients with multiple myeloma (MM), compared with lenalidomide and dexamethasone (Rd)...
On location

Can Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Skip Radiation Therapy?

Results from the Intergroup National Clinical Trials Network (NCTN) study S1001 demonstrated that 89% of patients with limited-stage diffuse large B-cell lymphoma (DLBCL) maintained...

DDGP Versus SMILE: Comparing Regimens for Extranodal Natural Killer T-Cell Lymphoma

In patients with extranodal natural killer T-cell lymphoma (ENKTL), treatment with the chemotherapy regimen of dexamethasone, cisplatin, gemcitabine, and pegasparaginase (DDGP) improved survival compared...

Current Issue

July 2021 Bonus Mid-Year Edition, Volume 7 Issue 9

This issue features conversations with ASH Clinical Research Training Institute graduates, highlights from the virtual ASCO and EHA annual meetings, and more.

Block title